FP7 logo euThe ESNATS project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F5-2008-201619

Embryonic Stem cell-based Novel Alternative Testing Strategies

Partners: Shering-Plough (formerly ORG)

Schering-PloughSchering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J.

In ESNATS, Schering-Plough is a member of the Steering Committee and will, as such, provide advice and requirements on industry needs for assay development and specify reference compounds to be tested.

Key staff involved in the project

Sjeng HorbachSjeng Horbach, PhD., Senior Director DMPK and Safety, Department of Pharmacology. He has a background in cytochrome P450 mediated metabolism, genetic toxicology and in in vitro toxicology. He is involved in the toxicity screening of new compounds, before they enter pre-clinical development. Also is his group working on the application of transcriptomics technologies in the prediction of toxicity as well as in the elucidation of toxicity mechanisms.

Further information: www.schering-plough.com

Top ^